Avoiding Kidney Injury:

Overview, Pathophysiology, & Definitions





Objectives

- Discuss incidence and impact of Acute Kidney Injury & Chronic Kidney Disease in surgical patients
- Review the pathophysiology related to AKI and CKD
- Identify definitions & stages of kidney disease
- Share registry definitions of kidney injury or failure & review ASPIRE AKI 01 measure
- For other recommendations to avoid AKI, reference additional toolkit components:
 - Avoiding Kidney Injury Recommendations for Adult Surgical Patients
 - Avoiding Kidney Injury Pediatrics
 - Avoiding Kidney Injury Obstetrics
 - Avoiding Kidney Injury Cardiac Surgery



AKI Incidence

13.3 million Patients per year develop AKI worldwide ¹	1.7 million Deaths per year worldwide attributed to AKI ¹	7-13% Surgical patients suffer with AKI ²	70% mortality rate for patients with sepsis and AKI ³
ଜନ	9% Non-cardiac inpatient surgery patients develop AKI ⁴	25% Of trauma patients develop AKI ⁵	52-56% Of patients admitted to ICU after surgery ⁶



Impact of AKI

- AKI can be an early indicator of multi-organ dysfunction with significant effects on mortality ⁷⁻⁹
- Effects of AKI can last years and lead to development of chronic kidney disease or ESRD, even for patients whose creatinine improves at the time of discharge ^{2,5,10-11}





AKI Impact

- In industrialized countries, acute kidney injury (all cause)...
 - Claims 300,000 lives annually
 - Contributes to 300,000 new CKD cases annually
 - Results in 170,000 end stage kidney disease diagnoses ¹²
- In the United States alone, AKI costs an estimated \$10 billion annually ¹³
- Compared to postoperative patients without AKI, patients with AKI are associated with:





CKD Incidence

→ Estimated global prevalence 11-13% ¹⁴

→ Over 1 in 7 adults in the United States have CKD ¹⁵

- → 90% do not know that they have CKD ¹⁵
- → 9th Leading cause of death in the US ¹⁶





CKD Impact

- 14.5% of Medicare patients age 65 and older have CKD ¹⁷
- Medicare spent \$120 billion on ESRD and CKD in 2019 (¹/₃ of all Medicare Fee for Service spending) ¹⁷

Yearly Medicare spending per beneficiary with non-ESRD CKD is over \$23,500, nearly double than for average Medicare beneficiary ¹⁷



No CKD

Non-ESRD CKD



Pathophysiology of Kidney Disease



Kidney Disease Overview - Conditions that affect structure and function of the kidneys $^{\rm 18}$

- Acute Kidney Injury
- Acute Kidney Disease
- Chronic Kidney Disease
- End Stage Renal Disease





Conditions can be categorized by length of time



Acute Kidney Injury: General Definition



Several AKI Classification Systems Exist:¹⁸

- a. RIFLE Risk, Injury, Failure, Loss, End Stage 2004
- b. AKIN Acute Kidney Injury Network 2007
- c. **KDIGO** Kidney Disease Improving Global Outcomes- 2012





*See slides 6-12 for classification system criteria & slide 21 for biomarker explanation.

AKI Pathophysiology



- Historically, cause of disease was divided into prerenal, renal (intrinsic), and post renal ¹⁸
- This approach does not account for multifactorial causes ¹⁸



Etiology: Prerenal



25% of cardiac output goes to the kidneys ⁷



Renal hypoperfusion leads to decreased GFR as an adaptive response. Water, sodium, and urea retained to conserve volume ²¹

- Prerenal AKI is the result of hypovolemia or low cardiac output ¹⁸
- No damage to renal parenchyma⁷
- Can progress to Intrinsic AKI if hypovolemia insult continues and damage occurs ²²

*Adapted from Makris 2016



Etiology: Prerenal Possible Causes ⁷

Impaired Cardiac Function: Congestive heart failure, acute myocardial infarction, massive pulmonary embolism

Increased Vascular resistance: Anesthesia, surgery, hepatorenal syndrome, NSAID medications, drugs that cause renal vasoconstriction

Systemic Vasodilation:

Anti-hypertensive medications, gram negative bacteremia, cirrhosis, anaphylaxis

Hypovolemia: Hemorrhage, volume depletion, renal fluid loss (over-diuresis), third space (burns, peritonitis, muscle trauma)



Etiology: Renal (Intrinsic)

- Results of injury to kidney structures: tubules, glomeruli, the interstitium, and intra-renal blood vessels ⁷
- Acute Tubular Necrosis (ATN) AKI from damage to tubules. This is the most common type of Intrinsic AKI ⁷





Etiology: Intrinsic Possible Causes ⁷

Interstitium: Infectious (bacterial, viral), medications (antibiotics, diuretics, NSAIDs, etc)

Vascular: Large vessels (bilateral renal artery stenosis, bilateral renal vein thrombosis), small vessels (vasculitis, malignant hypertension, atherosclerotic or thrombotic emboli, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura)



Tubular: Renal ischemia (shock, complication of surgery, hemorrhage, trauma, bacteremia, pancreatitis, pregnancy), nephrotoxic drugs (antibiotics, antineoplastic drugs, contrast media, organic solvents, anesthetic drugs, heavy metals) endogenous toxins (myoglobin, hemoglobin, uric acid)

Glomerular: Acute post infectious glomerulonephritis, Lupus nephritis, IgA glomerulonephritis, infective endocarditis, Goodpasture syndrome, Wegener disease



Etiology: Postrenal

- Caused by blockage of urinary flow in the urinary tract ¹⁸
- Obstruction $\rightarrow \uparrow$ intratubular pressure and \downarrow GFR ²²
- Leads to build up in the kidney ²²
- Quick resolution = best chance of kidney recovery ⁷





Etiology: Post Renal Possible Causes ⁷





Nephrolithiasis, blood clots,



Consequences of acute kidney injury on remote organ functions

AKI Impact on Organ Function

*Image Source: Gumbert et al. Anesthesiology 2020



AKI Risk Factors



Categories of AKI Risk Factors

- Patient-related, such as:
 - Diabetes
 - Hypertension
 - Sepsis
- Procedure-related, such as:
 - Cardiopulmonary bypass & duration
 - Emergency Surgery
 - Organ Transplant
- Anesthesia-specific, such as:
 - Vasopressor use
 - Diuretic use
 - Hypotension

KIDNEY DISEASE RISK FACTORS diabetes high blood pressure family history heart disease obesity race/ethnicity age



Patient Risk Factors ²³⁻²⁵

- Preoperative level of kidney function
- Chronic Vascular Disease
- Arterial Hypertension
- Cardiac Failure/Cardiac Decompensation
- Diabetes (insulin or oral therapy requirements)
- Acute medical conditions (sepsis, major surgery, mechanical ventilation, hemodynamic instability)

- Hypertension
- Peripheral Vascular Disease
- Congestive Heart Failure
- Sepsis
- Ascites
- Cerebrovascular disease
- Mild to Moderate preoperative renal insufficiency
- Age >65
- COPD
- Chronic Kidney Disease
- $BMI \ge 25$ (Overweight) (Ju 2018)

Patient-related risk factors are more strongly associated with mortality than the type of procedure ²³

Procedure Related Risk Factors ^{10, 23, 25}

- Gastric bypass surgery for morbid obesity- 8.5% incidence AKI
- Cardiopulmonary bypass (CPB) & duration
- Aortic cross clamping & duration
- Hemodilution (cardiac surgery)
- Duration of surgery
- Intraperitoneal surgery
- Repair of AAA

- Organ transplant (non-renal also)
 - Liver Transplant
 - 33% develop AKI
 - 17% require RRT
- Use of intra-aortic balloon pump
- Type of cardiac surgical procedure
- Intra-abdominal hypertension
- Emergency surgery
- Bleeding complications



Anesthesia-related Risk Factors

Potentially modifiable AKI risk factors in both cardiac and noncardiac surgery ^{10, 23, 25}

- Hemodilution
- Hemoglobin level
- Intraoperative transfusion
- Hypotension
- Inadequate oxygen delivery
- Use of diuretics
- Selective renal ischemia
- Ischemia reperfusion injury
- Bleeding complications
- Intraoperative Hypertension
- Nephrotoxic agents (eg abx, contrast agents)



Acute Kidney Injury Classification Systems



AKI Classification Systems: RIFLE

- First attempt at a unifying definition for AKI (then called acute renal failure) ²⁶
- Published in 2004, RIFLE graded AKI Stages and provided taxonomies for both severity and recovery ¹⁰
- Proposed 1 week timeframe for AKI Diagnosis ²⁷

	GFR Criteria	Urine output criteria		
R isk	Increased creatinine x1.5 or GFR decrease >25%	UO <0.5ml kg ⁻¹ h ⁻¹ x6h	High Sensitivity	
Injury	Increased creatinine x2 or GFR decrease >50%	UO <0.5ml kg ⁻¹ h ⁻ ¹ x12h		
Failure	Increased creatinine x3 or GFR decrease >75% or creatinine ≥4mg per 100mL (acute rise of ≥0.5mg per 100ml dI)	UO < 0.3 kg ⁻¹ h ⁻¹ x24h or anuria x12h (Oliguria)	High Specificity	
	Persistent ARF = complete >4 wee	e loss of renal function eks		
Loss				
E SRD	End Stage Renal Disease (>3 months)			
	Diagnostic criteria: - 1 week timeframe for AKI diagnosis - Grades patients based on the worse category for GFR/UO			

Image Source: Ricci, Cruz, & Ronco Kidney International 2008



AKI Classification Systems: RIFLE

- Previously over thirty different definitions of acute renal failure were in use ²⁶
- Caused shift in terminology: "Acute Renal Failure" → "Acute Kidney Injury"
- Highlighted importance of identifying changes in kidney function earlier to prevent failure ²⁸
- Validated in multiple studies for its ability to classify patients and was strongly tied to patient outcomes in the acutely ill ²⁸



AKI Classification Systems: RIFLE

Limitations

- Smaller increases in SCr than those defined in "Risk" (<1.5x) are associated with poor outcomes ²⁷
- Urine output component unreliable (may be influenced by other factors such as diuretic use) ²⁷
- When using estimated GFR in place of a true baseline GFR, the formulas that estimate GFR presume a "steady state" for GFR that is absent in patients with acutely changing kidney function ²⁷
- Urine output alone used for staging was not found to be an accurate predictor of AKI; Cr and urine output should be assessed together for accurate staging & as a predictor of ICU mortality ²⁹



	RIFLE C GFR Criteria	Urine output criteria		[ritoria
R isk	Increased creatinine x1.5 or	UO <0.5ml kg ⁻¹ h ⁻¹ x6h	High	Removed GF	R Cr Criteria	Urine output criteria
			Sensitivity	Stage 1	Increased creatinine x1.5 or ≥ 0.3mg/dl	UO <0.5ml/kg/hr x6 hr
Injury	GFR decrease >50%	UU <0.5ml kg ⁻ 'n ⁻ 'x12n		Stage 2	Increased creatinine x2	UO <0.5ml/kg/hrx12h
Failure	Increased creatinine x3 or GFR decrease >75% or creatinine ≥4mg per 100mL (acute rise of ≥0.5mg per 100ml dl)	UO < 0.3 kg ⁻¹ h ⁻¹ x24h or anuria x12h (Oliguria)	High Specificity	Stage 3	Increased creatinine x3 or Cr ≥ 4 mg/dl (with acute rise of ≥0.5mg/dl)	UO < 0.3 ml/kg/hr x24h or anuria x12h (Oliguria)
Loss	Persistent ARF = complete I week	oss of renal function >4 s	N	ew RRT Staging	Patients who receive renal re are considered to have me irrespective of the stage that commenceme	placement therapy (RRT) t the criteria for stage 3 they are in at the time of ent of RRT
E SRD	End Stage Renal Dise	ease (>3 months)	Intro tir	oduced 48h meframe	Diagnostic criteria: - Serum creatinine me - Grades patients on u	easured <mark>over 48 hours</mark> urine output and change in
	Diagnostic criteria: - 1 week timeframe for - Grades patients base for GFR/UO	r AKI diagnosis ed on the worse category			SCr over <mark>48 hours</mark> - 7 day timeframe for s	

IVE

AKI Classification Systems: Acute Kidney Injury Network (AKIN)^{27,30}

AKI Classification Systems: AKIN

- Introduced in 2007 to improve accuracy after RIFLE release ²⁷
- Relies on serum creatinine measured over 48 hours but does not use GFR
- Grades patients on urine output and change in SCr over 48 hours
- Higher diagnostic accuracy than RIFLE ³⁰



AKI Classification Systems: AKIN

Limitations

- 48 hour timeframe for diagnosis of AKI may miss slowly progressing AKI ²⁷
- While diagnosis of AKI is based on a change in SCr over 48 hours, a 1 week timeframe is used for staging AKI²⁷



UO criteria Cr Criteria Urine output criteria unchanged 1 Increased creatinine UO <0.5ml/kg/hr for x1.5-1.9 from baseline 6-12hr SCr criteria or mostly ≥ 0.3 mg/dl unchanged from AKIN Increased creatinine UO <0.5ml/kg/hr ≥ 2 x2.0-2.9 from baseline 12h Removed acute 3 Increased creatinine x3 UO < 0.3 ml/kg/hr for rise criteria. Kept from baseline OR SCr ≥ ≥ 24h **RRT** criteria from 4.0mg/dl OR RRT or anuria \geq 12h AKIN Kept SCr increase of $\geq 0.3 \text{ mg/dl}$ within 48 hours from AKIN Diagnostic criteria for AKI: SCr increase ≥0.3mg/dl within 48h OR SCr increase ≥1.5 times baseline, which Used 7 day is known or presumed to have occured timeframe for within the last 7 days OR 1.5X increase in Urine volume < 0.5 ml/kg for 6h -SCr from RIFLE

AKI Classification Systems: KDIGO Criteria (2012) ³¹

RIFLE - 2004	AKIN - 2007	
--------------	-------------	--

	GFR Criteria	Urine output criteria		Cr Criteria	Urine output criteria		GFR Criteria	Urine output criteria
R isk	Increased creatinine x1.5 or GFR decrease >25%	UO <0.5ml kg ⁻¹ h ⁻ ¹ x6h	1	Increased creatinine x1.5 or ≥ 0.3mg/dI	UO <0.5ml/kg/hr x6 hr	1	Increased creatinine x1.5-1.9 from baseline or ≥ 0.3 mg/dl	UO <0.5ml/kg/hr for 6-12hr
Injury	Increased creatinine x2 or GFR decrease >50%	UO <0.5ml kg ⁻¹ h ⁻ ¹ x12h	2	Increased creatinine x2	UO <0.5ml/kg/hrx12h	2	Increased creatinine x2.0-2.9 from baseline	UO <0.5ml/kg/hr ≥ 12h
Failure	Increased creatinine x3 or GFR decrease >75% or creatinine ≥4mg per 100mL (acute rise of ≥0.5mg per 100ml dl)	UO < 0.3 kg ^{-1h-} ¹ x24h or anuria x12h (Oliguria)	3	Increased creatinine x3 or Cr ≥ 4 mg/dl (with acute rise of ≥0.5mg/dl)	UO < 0.3 ml/kg/hr x24h or anuria x12h (Oliguria)	3	Increased creatinine x3 from baseline OR SCr ≥ 4.0mg/dl OR RRT	UO < 0.3 ml/kg/hr for ≥ 24h or anuria ≥ 12h
				Patients who receive rena	I replacement therapy			
	Persistent ARF = com function >4	plete loss of renal weeks		for stage 3 irrespective of are in at the time of com	f the stage that they mencement of RRT		Diagnostic criteria for AKI: - SCr increase ≥0.3i - SCr increase ≥1.5	mg/dl within 48h OR times baseline, which
Loss				Diagnostic criteria: is known or presumed to have a structure of the units o			med to have occured	
E SRD	End Stage Renal Dise	ease (>3 months)					.5 ml/kg for 6h	
	Diagnostic criteria: - 7 day timefram - Grades patients	e for AKI diagnosis based on the worse		 Grades patients of change in SCr ov 7 day timeframe 	for staging AKI			

Differences between RIFLE, AKIN, & KDIGO Staging/Criterion

- RIFLE, AKIN, & KDIGO have been shown to have similar predictive ability for in-hospital mortality ³⁰
- In one 2017 study, RIFLE and KDIGO diagnosed more patients with AKI than AKIN ³⁰
- AKIN may under diagnose AKI as compared to RIFLE and KDIGO ³¹



Kidney Disease: Progression from AKI to CKD and/or Renal Failure

- KDIGO Clinical Practice Guideline for AKI (2012) recommends patients follow-up within 3 months after experiencing AKI after surgery to assess for progression to CKD 33
- Patients who recover from AKI may not return to baseline kidney function irreversible decline in kidney function is more likely for patients \geq 65 years old ³⁴



Of CKD patients who experience an episode of AKI after cardiac surgery will progress to a worse CKD class ³²





Chronic Kidney Disease



Chronic Kidney Disease Classification



- CKD Classification based on:
 - a. Presence or absence of systemic disease
 - b. Location of pathology within kidney



Nature Reviews | Nephrology



Chronic Kidney Disease Definition

- Abnormalities in kidney structure or function that persist beyond 90 days ¹⁹
- Can result from a variety of causes of kidney damage
- Higher risk of end stage renal disease (ESRD) ³³

Criteria for CKD (either of the following present for >3 months)				
Markers of kidney damage (one or more)	Albuminuria (AER≥30mg/24h; ACR≥30mg/g [≥3mg/mmol]) Urine sediment abnormalities Electrolyte and other abnormalities due to tubular disorders Abnormalities detected by histology Structural abnormalities detected by imaging History of kidney transplantation			
Decreased GFR	GFR<60ml/min/1.73m ² (GFR categories G3a-G5)			



GFR Categories in CKD

Category	GFR (ml/min/1.73m ²)	Terms
G1	>90	Normal or high
G2	60-89	Mildly decreased*
G3a	45-59	Mildly to moderately decreased
G3b	30-44	Moderately to severely decreased
G4	15-29	Severely decreased
G5	<15	Kidney Failure

*Relative to young adult level

In the absence of evidence of kidney damage, neither GFR category G1 or G2 fulfill the criteria for CKD

Albuminuria categories in CKD

Category	Albumin excretion rate	Albumin to cre	atinine ratio (Approximate equivalent)	Terms
A1	<30 mg/24h	<3 mg/mmol	<30 mg/g	Normal to mildly increased
A2	30-300 mg/24h	3-30 mg/mmol	30-300 mg/g	Moderately increased*
A3 *Relative to vo	>300 mg/24h	>30 mg/mmol	>300 mg/g	Severely increased**

**Including nephrotic syndrome (albumin excretion usually >2200mg/34 hours [ACR>220mg/g; >220mg/mmol])



Figure Source: 2012 KDIGO Clinical Practice Guidelines for Chronic Kidney Disease

CKD Staging

CKD Pathophysiology

	Examples of systemic diseases affecting the kidney	Examples of primary kidney disease (absence of systemic disease affecting the kidney)
Glomerular diseases	Diabetes, systemic autoimmune diseases, systemic infections, drugs, neoplasia (including amyloidosis)	Diffuse, focal or crescentic proliferative GN; focal and segmental glomerulosclerosis, membranous nephropathy, minimal change disease
Tubulointerstitial diseases	Systemic infections, autoimmune, sarcoidosis, drugs, urate, environmental toxins (lead, aristolochic acid), neoplasia (myeloma)	Urinary-tract infections, stones, obstruction
Vascular diseases	Atherosclerosis, hypertension, ischemia, cholesterol emboli, systemic vasculitis, thrombotic microangiopathy, systemic sclerosis	ANCA-associated renal limited vasculitis, fibromuscular dysplasia
Cystic and congenital diseases	Polycystic kidney disease, Alport syndrome, Fabry disease	Renal dysplasia, medullary cystic disease, pondocytopathies



Figure Source: 2012 KDIGO Clinical Practice Guidelines for Chronic Kidney Disease

Risk of Progression of AKI to CKD

 Risk of progression to advanced chronic kidney disease has been developed by an externally validated prediction model among hospital inpatients experiencing AKI, with all data available at the time of detection of acute kidney injury³⁹.

	Model 3
Dradictors	Age, sex, AKI stage,
Predictors	Baseline Scr
Intercept	-9.1857
Age (years)	0.0126
Sex (female)	1.0218
AKI (KDIGO definition)	
Stage1	
Stage2	0.7893
Stage3	1.9232
Baseline Scr (mg/dL)	3.7321
p= <i>e</i> ^(-9.1857+0.0126*age+1.	0218*sex+0.7893*AKI2+1.9232*AKI3+3.7321*BaselineSCr)
(1+e^-9.1857+0.0126*age+1.0	218*sex+0.7893*AKI2+1.9232*AKI3+3.7321*BaselineSCr)
where:	
Age is continuous in years	

Sex: male=0, female=1

- Stage 1 AKI: AKI2=0 and AKI3=0
- Stage 2 AKI: AKI2=1 and AKI3=0
- Stage3 AKI: AKI2=0 and AKI3=1

Baseline Scr is continuous in mg/dL



Prediction model of CKD progression after AKI

Emerging Research: Biomarkers



Biomarkers

Current research activities aim to identify new biomarkers, which are released before sCR increases and/or urinary output declines ²³

- The production and release of possible biomarkers of early tubular stress is triggered by surgical trauma, cardiopulmonary bypass, or other noxious events
- Several issues have to be addressed before these biomarkers can be introduced into daily clinical routine
 - Lack of sensitivity that is related to the etiological heterogeneity of AKI, and the lack of specificity that seems related to extrarenal causes for fluctuations in serum or urine concentration of the biomarkers
 - NGAL- neutrophil-gelatinase-associated lipcalin → considered the troponin of the kidneys, can only predict AKI in patients with prior normal kidney function
 - Tissues inhibitor of metalloproteinases-2 (TIMP-2)
 - Insulin-like growth factor binding protein (IGFBP7)



Subclinical AKI

- Recently defined with the introduction of biomarkers
- Increased biomarker presence without fulfilling KDIGO criteria is considered subclinical ³⁵
 - NGAL neutrophil gelatinase-associated lipocalin
 - Excreted when there is tubular damage ³⁵
 - Proposed cut off for tubular damage 100-150 ng/mL
- Functional AKI meets KDIGO criteria but does not have biomarker increase
- Subclinical AKI are associated with adverse outcomes despite not meeting KDIGO AKI criteria ³⁶

	KDIGO Criteria	Biomarker Increase
Functional AKI	YES	×
Subclinical AKI	×	YES



Registry Definitions: Kidney Disease



American College of Surgeons (ACS) - NSQIP



AMERICAN COLLEGE OF SURGEONS Inspiring Quality: Highest Standards, Better Outcomes

Progressive Renal Insufficiency

A rise in creatinine of >2 mg/dl from preoperative value, but with no requirement for preoperative (within the 2 week timeframe prior to surgery) or postoperative dialysis

Acute Renal Failure Requiring Dialysis

In a patient who did not require dialysis preoperatively (within the 2 week timeframe prior to surgery), worsening of renal dysfunction postoperatively requiring dialysis (hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration)





American College of Surgeons (ACS) - Trauma



Acute Kidney Injury- Stage 3*

- 1. 3 times baseline (SCr) or
- 2. Increase in SCr to \geq 4.0 mg/dl (\geq 353.6 μ mol/l) *or*
- 3. Initiation of renal replacement therapy
 - *KDIGO Criterion Used
 - For patients < 18 years:
- 1. Decrease in eGFR to <35 ml/min per 1.73 m² or
- 2. Urine output <0.3 ml/kg/h for > 24 hours or
- 3. Anuria for > 12 hours



Source: NTDS 2020 Data Dictionary

Michigan Trauma Quality Improvement Program (MTQIP) $M \cdot TQIP$

Acute Renal Insufficiency

1) Rise in creatinine of >2 mg/dl from baseline value, but with no requirement for dialysis. Assume a baseline value of 1.0 mg/dl in the absence of additional information regarding the patient's pre-injury renal function.

Acute Kidney Injury*

- 1) Increase creatinine x3 or GFR decrease > 75% or
- 2) Urine output criteria: UO < 0.3ml/kg/hr x 24 hours *or*
- 3) Anuria x 12 hours or
- 4) Requirement of renal replacement therapy

*RIFLE criterion used

Source: Michigan Trauma Quality Improvement Program Data Dictionary



Society of Thoracic Surgeons- Cardiac



Post-op Renal Failure Definition:

1. Increase in serum creatinine level 3.0 x greater than baseline, or serum creatinine level \geq 4 mg/dL (acute rise must be at least 0.5 mg/dl) **or**

2. A new requirement for dialysis postoperatively

*KDIGO Stage 3 Criterion Used

Post-Op-Renal-Dialysis: New requirement for dialysis postoperatively, which may include hemodialysis, peritoneal dialysis

Post-Op-Dialysis Required After Discharge

Post-Op-Dialysis Duration

Source: STS Adult Cardiac Surgery Database Data Specifications



Registry Definitions: STS- Thoracic



Renal Failure - KDIGO Stage 3 Criteria

1. Increase in serum creatinine level 3.0 x greater than baseline, or serum creatinine level >=4 mg/dL. Acute rise must be at least 0.5 mg/dl *OR*

2. A new requirement for dialysis postoperatively



MPOG Measure Definition: AKI 01

- ASPIRE Definition of AKI: Baseline creatinine increased more than 1.5 times within 7 postoperative days OR the baseline creatinine level increased by ≥ 0.3 mg/dL within 48 hours after anesthesia end.
- Baseline serum creatinine is defined as the most recent serum creatinine resulted in the last 60 days preoperatively.
- KDIGO Criterion used



Acute Kidney Injury

AKI-01: Acute Kidney Injury



Summary

- 1. Several definitions of AKI exist but KDIGO is most widely accepted
- 1. Adverse effects of AKI can last years, even for patients whose creatinine improves at the time of discharge ^{5,10-11}
- 1. Patient-related risk factors are more strongly associated with mortality than the type of procedure ²³
- 1. Surgical registries have begun to collect data regarding kidney injury, though definitions vary, these outcomes can be helpful for both quality improvement and research purposes.
- 1. For recommendations to avoid AKI, reference additional toolkit components:
 - Avoiding Kidney Injury Recommendations for Adult Surgical Patients
 - Avoiding Kidney Injury Pediatrics
 - Avoiding Kidney Injury Obstetrics
 - Avoiding Kidney Injury Cardiac Surgery



1 Mehta RL, Cerdá J, Burdmann EA, Tonelli M, García-García G, Jha V, Susantitaphong P, Rocco M, Vanholder R, Sever MS, Cruz D, Jaber B, Lameire NH, Lombardi R, Lewington A, Feehally J, Finkelstein F, Levin N, Pannu N, Thomas B, Aronoff-Spencer E, Remuzzi G: International Society of Nephrology's Oby25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 2015; 385:2616–43

2 Turan A, Cohen B, Adegboye J, Makarova N, Liu L, Mascha EJ, Qiu Y, Irefin S, Wakefield BJ, Ruetzler K, Sessler DI: Mild Acute Kidney Injury after Noncardiac Surgery Is Associated with Long-term Renal Dysfunction: A Retrospective Cohort Study. Anesthesiology 2020; 132:1053–61

3 Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004; 351:159-69

4 Mathis MR, Naik BI, Freundlich RE, Shanks AM, Heung M, Kim M, Burns ML, Colquhoun DA, Rangrass G, Janda A, Engoren MC, Saager L, Tremper KK, Kheterpal S, Multicenter Perioperative Outcomes Group Investigators: Preoperative Risk and the Association between Hypotension and Postoperative Acute Kidney Injury. Anesthesiology 2019 doi:10.1097/ALN.000000000003063

5 Bihorac A, Delano MJ, Schold JD, Lopez MC, Nathens AB, Maier RV, Layon AJ, Baker HV, Moldawer LL: Incidence, clinical predictors, genomics, and outcome of acute kidney injury among trauma patients. Ann Surg 2010; 252:158–65

6 Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen A-M, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA: Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015; 41:1411–23



7 Makris K, Spanou L: Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes. Clin Biochem Rev 2016; 37:85–98

8 Kork F, Balzer F, Spies CD, Wernecke K-D, Ginde AA, Jankowski J, Eltzschig HK: Minor Postoperative Increases of Creatinine Are Associated with Higher Mortality and Longer Hospital Length of Stay in Surgical Patients. Anesthesiology 2015; 123:1301–11

9 O'Connor ME, Hewson RW, Kirwan CJ, Ackland GL, Pearse RM, Prowle JR: Acute kidney injury and mortality 1 year after major non-cardiac surgery. Br J Surg 2017; 104:868–76

10 Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A: Acute kidney injury is associated with increased long-term mortality after cardiothoracic surgery. Circulation 2009; 119:2444–53

11 O'Connor ME, Kirwan CJ, Pearse RM, Prowle JR: Incidence and associations of acute kidney injury after major abdominal surgery. Intensive Care Med 2016; 42:521–30

12 Kashani K, Shao M, Li G, Williams AW, Rule AD, Kremers WK, Malinchoc M, Gajic O, Lieske JC: No increase in the incidence of acute kidney injury in a population-based annual temporal trends epidemiology study. Kidney Int 2017; 92:721–8

13 Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16:3365–70

14 Hill NR, Fatoba ST, Oke JL, Hirst JA, O'Callaghan CA, Lasserson DS, Hobbs FDR: Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0158765



15 1 in 7 American Adults Estimated to Have Chronic Kidney Disease 2017 at <<u>https://www.kidney.org/news/one-seven-american-adults-estimated-to-have-chronic-kidney-disease</u>>

16 Chronic Kidney Disease Basics | Chronic Kidney Disease Initiative | CDC 2020 at <<u>https://www.cdc.gov/kidneydisease/basics.html</u>>

17 2019 ADR Reference Tables at <<u>https://www.usrds.org/reference.aspx</u>>

18 Gumbert SD, Kork F, Jackson ML, Vanga N, Ghebremichael SJ, Wang CY, Eltzschig HK: Perioperative Acute Kidney Injury. Anesthesiology 2020; 132:180–204

19 Cole SP: Stratification and Risk Reduction of Perioperative Acute Kidney Injury: An Update. Anesthesiol Clin 2018; 36:539–51

20 Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA, Acute Disease Quality Initiative Workgroup 16.: Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 2017; 13:241–57

21 Blantz RC: Pathophysiology of pre-renal azotemia. Kidney Int 1998; 53:512–23

22 Basile DP, Anderson MD, Sutton TA: Pathophysiology of acute kidney injury. Compr Physiol 2012; 2:1303–53

23 Meersch M, Schmidt C, Zarbock A: Perioperative Acute Kidney Injury: An Under-Recognized Problem. Anesth Analg 2017; 125:1223–32



24 Romagnoli S, Ricci Z, Ronco C: Perioperative Acute Kidney Injury: Prevention, Early Recognition, and Supportive Measures. Nephron 2018; 140:105–10

25 Meersch M, Volmering S, Zarbock A: Prevention of acute kidney injury. Best Pract Res Clin Anaesthesiol 2017; 31:361–70

26 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204–12

27 Cruz DN, Ricci Z, Ronco C: Clinical review: RIFLE and AKIN--time for reappraisal. Crit Care 2009; 13:211

28 Kellum JA, Bellomo R, Ronco C: The Concept of Acute Kidney Injury and the RIFLE Criteria 2007, pp 10–6

29 Cruz DN, Ronco C: Acute kidney injury in the intensive care unit: current trends in incidence and outcome 2007; 11:p 149

30 Pereira M, Rodrigues N, Godinho I, Gameiro J, Neves M, Gouveia J, Costa E Silva Z, Lopes JA: Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the "Risk, Injury, Failure, Loss of kidney function, End-stage kidney disease" (RIFLE), Acute Kidney Injury Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) classifications. Clin Kidney J 2017; 10:332–40

31 Fujii T, Uchino S, Takinami M, Bellomo R: Validation of the Kidney Disease Improving Global Outcomes criteria for AKI and comparison of three criteria in hospitalized patients. Clin J Am Soc Nephrol 2014; 9:848–54



32 Ishani A, Nelson D, Clothier B, Schult T, Nugent S, Greer N, Slinin Y, Ensrud KE: The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death. Arch Intern Med 2011; 171:226–33

33 KDIGO. 2012. "KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease." <u>https://kdigo.org/wp-content/uploads/2017/02/KDIGO 2012 CKD GL.pdf</u>.

34 Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81:442–8

35 Geus HRH de, Ronco C, Haase M, Jacob L, Lewington A, Vincent J-L: The cardiac surgery-associated neutrophil gelatinaseassociated lipocalin (CSA-NGAL) score: A potential tool to monitor acute tubular damage. J Thorac Cardiovasc Surg 2016; 151:1476–81

36 Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling C-R, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR: The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011; 57:1752–61

37 Grams ME, Sang Y, Coresh J, Ballew S, Matsushita K, Molnar MZ, Szabo Z, Kalantar-Zadeh K, Kovesdy CP: Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data. Am J Kidney Dis 2016; 67:872–80



38 Hobson C., Ozrazgat-Baslanti T., Kuxhausen A., et. al.: Cost and mortality associated with postoperative acute kidney injury. Ann Surg 2015; 261: pp. 1207-1214.

39 James, Matthew T., Neesh Pannu, Brenda R. Hemmelgarn, Peter C. Austin, Zhi Tan, Eric McArthur, Braden J. Manns, et al. 2017. "Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury." *JAMA: The Journal of the American Medical Association* 318 (18): 1787–97.

